API Product   :    Indacaterol Maleate
CEP   :    -
WCC   :    -
Therapeutic Use    :    Chronic Obstructive Pulmonary Disease(COPD)
Chronic Obstructive Pulmonary Disease(COPD)
Originator   :    Novartis
CAS No.    :    312753-06-3
Trade Name.   :    Onbrez, Arcapta
Molecular Weight   :    392.490 g/mol
Molecular Formula   :    C24H28N2O3
Indacaterol is used to treat trouble breathing and wheezing due to a certain ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and/or emphysema). It is used if your breathing problems are not controlled with other medication (such as a quick-relief inhaler).
Indacaterol (INN) is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It was approved by the European Medicines Agency (EMA) under the trade name Onbrez Breezhaler on November 30, 2009, and by the United States Food and Drug Administration (FDA), under the trade name Arcapta Neohaler, on July 1, 2011. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered as an aerosol formulation through a dry powder inhaler.